Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Sistema de Sutura Endoscópica OverStitch NXT

26 de outubro de 2026 atualizado por: Boston Scientific Corporation

Reunião de Resultados em Populações Asiáticas Obesas Elegíveis sobre a Segurança e Eficácia do Ensaio Overstitch ESG

To demonstrate the safety and efficacy of OverStitch NXT Endoscopic Suture System for endoscopic sleeve gastroplasty(ESG) in obese populations to support the registration of OverStitch NXT for ESG indication.

Visão geral do estudo

Status

Recrutamento

Condições

Descrição detalhada

The study is a prospective, multicenter, randomized controlled trial

This study is planned to be conducted at 10 sites, with each center initially enrolling 2 roll-in cases (totaling 20 cases). After each site completes the enrollment of its roll-in cases, the remaining subjects will be randomly divided into two groups (the treatment group and the control group) via a central randomization system. Each group will ultimately enroll 58 subjects, resulting in a total sample size of 136 for the study.

Roll-in Cases: ESG combined with lifestyle management for 12 months. treatment group: ESG combined with lifestyle management for 12 months. control group: Lifestyle management alone for 12 months, followed by evaluation. Eligible participants may undergo ESG afterward.

Tipo de estudo

Intervencional

Inscrição (Estimado)

136

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

  • Nome: Shutian Zhang

Locais de estudo

    • China/Beijing
      • Beijing, China/Beijing, China, 100050
        • Recrutamento
        • Beijing Friendship Hospital, Affiliated to Capital Medical University
        • Contato:
          • L
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Aged 18 years or older, or subjects who have reached the legal age for signing informed consent in accordance with local laws and regulations.
  2. BMI ≥ 32.5 kg/m²; or BMI ≥ 27.5 kg/m² combined with type 2 diabetes mellitus (regardless of the effectiveness of medical treatment for type 2 diabetes); or BMI between 27.5 kg/m² and 32.5 kg/m² with ineffective medical weight loss or combined with other obesity-related diseases for which medical treatment is ineffective.
  3. Willing to comply with the long-term strict dietary restrictions required by the surgery.
  4. Capable of providing informed consent, able to complete all routine follow-up visits, and willing to abide by the protocol requirements, including signing the informed consent form, completing relevant examinations, and receiving dietary counseling.
  5. Females of childbearing potential (i.e., premenopausal or not sterilized) must agree to use adequate contraceptive measures.

Exclusion Criteria:

  1. History of foregut or gastrointestinal (GI) surgery (except uncomplicated cholecystectomy or appendectomy)
  2. Prior gastrointestinal surgery with sequelae, i.e. obstruction, and/or adhesive peritonitis or known abdominal adhesions.
  3. Prior open or laparoscopic bariatric surgery.
  4. Prior surgery of any kind on the esophagus or any type of hiatal hernia surgery.
  5. Any inflammatory disease of the gastrointestinal tract including severe (LA Grade C or D) esophagitis, gastric ulceration, duodenal ulceration, specific inflammation such as Crohn's disease, and the doctor judges that it may affect the operation or efficacy of ESG.
  6. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresia or stenosis.
  7. History of gastrointestinal stromal tumors, gastrointestinal cancer, low-grade or high-grade gastric intraepithelial neoplasia, or familial or non-familial adenomatous polyposis syndrome.
  8. Gastric masses or untreated gastric polyps with a diameter > 1 cm.
  9. Hiatal hernia (Z-line displacement above the diaphragm > 4 cm) or severe/refractory gastroesophageal reflux symptoms, which the physician judges may affect the performance or prognosis of ESG.
  10. Structural abnormalities of the esophagus or pharynx that may impede endoscopic passage (e.g., strictures or diverticula), which the physician judges may affect the performance or prognosis of ESG.
  11. Gastrointestinal motility disorders (e.g., achalasia, severe esophageal motility disorders, gastroparesis, or intractable constipation), which the physician judges may affect the performance or prognosis of ESG.
  12. Evidence of untreated psychiatric or eating disorders, such as major depression, schizophrenia, substance abuse, binge eating disorder, or bulimia nervosa.
  13. Coagulopathy with INR > 1.5 that cannot be corrected (per physician's judgment) or requirement for continuous full anticoagulant therapy, and/or any underlying diseases associated with high bleeding risk.
  14. Insulin-dependent diabetes mellitus (type 1 or type 2), or high likelihood of requiring insulin therapy within the next 12 months.
  15. Decompensated cirrhosis, or acute/chronic liver dysfunction that the physician judges make the subject unsuitable for ESG treatment.
  16. Diagnosis of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma) or immunocompromise, which the physician assesses may affect the performance or prognosis of ESG.
  17. Known history of endocrine diseases affecting body weight (e.g., Cushing's syndrome, uncontrolled hypothyroidism, or hyperthyroidism), which the physician assesses may affect the performance or prognosis of ESG.
  18. Anemia: Hemoglobin (Hgb) < 110 g/L for females; Hgb < 120 g/L for males.
  19. Any other medical conditions precluding elective endoscopy, such as poor general health, history of severe renal, hepatic, cardiac, and/or pulmonary diseases, and/or severe or uncontrolled psychiatric illnesses or abnormalities that may impair the patient's ability to understand or comply with follow-up visits and lifestyle interventions.
  20. Active psychological issues as determined by a psychologist or psychiatrist, precluding participation in lifestyle modification programs.
  21. Unwillingness to participate in the established medically supervised dietary and behavioral modification programs, as well as routine medical follow-up.
  22. Daily treatment with prescribed high-dose aspirin (> 80 mg per day), non-steroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, anticoagulants, corticosteroids, immunosuppressants, or other gastric irritant medications.
  23. Interval use of medications that may be affected by changes in gastric emptying (e.g., antiepileptic drugs or antiarrhythmic drugs).
  24. Inability or unwillingness to take prescribed proton pump inhibitor (PPI) medications.
  25. Current use of weight loss medications or other weight loss devices or use within the past 90 days.
  26. Current participation in a clinical trial involving investigational drugs or devices, or participation in such a trial within 30 days prior to enrollment in this study.
  27. Use of intragastric devices within 30 days prior to this study, which the physician assesses may affect the performance or prognosis of ESG.
  28. Unwillingness to avoid any reconstructive and/or plastic surgeries that may affect body weight during the study (e.g., mammoplasty, liposuction).
  29. Other conditions deemed unsuitable for endoscopy or ESG treatment by the investigator, including but not limited to conditions that the investigator believes may expose the subject to significant risks, confound study results, increase risks associated with endoscopy and/or endoscopic procedures, or substantially interfere with the subject's participation in the study.
  30. Pregnancy, lactation, or intention to become pregnant during the study (for females of childbearing potential).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: Roll-in Cases

ESG combined with lifestyle management for 12 months

The OverStitch NXT Endoscopic Suture System is indicated for the endoscopic placement of anchor-sutures. Anchor sutures can be placed for endoscopic sleeve gastroplasty(ESG).

Experimental: Treatment group

ESG combined with lifestyle management for 12 months.

The OverStitch NXT Endoscopic Suture System is indicated for the endoscopic placement of anchor-sutures. Anchor sutures can be placed for endoscopic sleeve gastroplasty(ESG).

Sem intervenção: Control group

Lifestyle management alone for 12 months, followed by evaluation. Eligible participants may undergo ESG afterward.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
%TBWL (Defined as the percentage of total body weight loss)
Prazo: At 12 months after the intervention.

%TBWL is defined as the percentage of total body weight loss

At 12 months after the intervention.
The response rate at the 12th month after the intervention
Prazo: At 12 months after the intervention

Response is defined as having a percentage of total body weight loss (%TBWL) of ≥ 5%

At 12 months after the intervention

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Shutian Zhang, Dr, Beijing Friendship Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

6 de agosto de 2026

Conclusão Primária (Estimado)

31 de outubro de 2028

Conclusão do estudo (Estimado)

31 de outubro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

30 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de novembro de 2025

Primeira postagem (Real)

11 de dezembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

27 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

26 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • E7241

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever